Oculis Holding Förvaltning

Förvaltning kriterier kontrolleras 2/4

Oculis Holding VD är Riad Sherif, utsedd i Dec 2017, har en anställningstid på 8.42 år. äger direkt 2.18% av företagets aktier, värda $ 39.90M. Den genomsnittliga mandatperioden för ledningsgruppen och styrelsen är 2.3 år respektive 3.5 år.

Viktig information

Riad Sherif

Verkställande direktör

n/a

Total ersättning

VD-lön i procent	n/a
Anställning som VD	8.4yrs
Ägande av VD	2.2%
Ledningens genomsnittliga anställningstid	2.3yrs
Styrelsens genomsnittliga mandatperiod	3.5yrs

Senaste uppdateringar av ledningen

Recent updates

Seeking Alpha • Jan 21

Oculis Is An Interesting Growth Bet On Non-Invasive Eye Care

Summary Oculis' main value driver appears to be OCS-01, which targets a respectable $4 billion DME TAM with its non-invasive eye drops. Eye injections are tough on patients, so this bodes well for OCS-01. OCS-05 and OCS-02 also target interesting TAMs in neuro-ophthalmology and DMD. OCS’s cash runway should last until late 2026, but if they don’t generate an FDA-approved product soon, it could become an issue for shareholders. Still, I see a few catalysts with upcoming regulatory milestones, like an NDA for OCS-01 in Q1, that could help sustain OCS stock’s valuation. I recommend a DCA strategy because Oculis stock might consolidate after such an impressive rally recently. Read the full article on Seeking Alpha

Seeking Alpha • Nov 04

Oculis: Lack Of Coverage Only Real Risk For This Solid Company

Summary Oculis has multiple late-stage programs and catalysts. Trading volume is low, and there's hardly any coverage in the US. Barring the low liquidity, OCS looks attractive. Read the full article on Seeking Alpha

VD OCH KONCERNCHEF

Riad Sherif (57 yo)

8.4yrs

Anställning

Dr. Riad Sherif, MD, MBA, has been the Chief Executive Officer and Director of Oculis Holding AG (formerly known as Oculis SA) since December 2017. He is Chief Executive Officer and Director of Oculis ehf....

Ledningsgrupp

Namn	Position	Anställning	Kompensation	Ägarskap
Riad Sherif	CEO & Director	8.4yrs	inga uppgifter	2.18% $ 39.9m
Sylvia Cheung	Chief Financial Officer	5.7yrs	inga uppgifter	0.12% $ 2.3m
Gudrun Bachmann	Chief Technology Officer	1.7yrs	inga uppgifter	inga uppgifter
Ramin Tadayoni	Chief Scientific Officer	2.2yrs	inga uppgifter	inga uppgifter
Katie Kazem	Chief Legal Officer	less than a year	inga uppgifter	inga uppgifter
Virginia Dean	Chief Human Resources Officer	2.3yrs	inga uppgifter	inga uppgifter
Páll Jóhannesson	Chief Business Officer	5.7yrs	inga uppgifter	0.43% $ 7.9m
Rebecca Weil	Chief Commercial Officer	2.7yrs	inga uppgifter	inga uppgifter
Snehal Shah	President of Research & Development	2.1yrs	inga uppgifter	inga uppgifter
Sharon Klier	Chief Development Officer	1.8yrs	inga uppgifter	inga uppgifter
Isabelle de Chambrier	Senior Vice President of Quality	2.7yrs	inga uppgifter	inga uppgifter

2.3yrs

Genomsnittlig anställningstid

53.5yo

Genomsnittlig ålder

Erfaren ledning: OCS s ledningsgrupp anses vara erfaren ( 2.3 års genomsnittlig anställningstid).

Styrelseledamöter

Namn	Position	Anställning	Kompensation	Ägarskap
Riad Sherif	CEO & Director	8.4yrs	inga uppgifter	2.18% $ 39.9m
Martijn Kleijwegt	Independent Director	3.2yrs	inga uppgifter	0.80% $ 14.6m
Eric Donnenfeld	Chair of Cornea Scientific Advisory Board	no data	inga uppgifter	inga uppgifter
Anthony Rosenberg	Independent Chairman	8.1yrs	inga uppgifter	0.20% $ 3.7m
Christophe Baudouin	Member of Scientific Advisory Board	3.5yrs	inga uppgifter	inga uppgifter
Peter Kaiser	Member of Scientific Advisory Board	3.5yrs	inga uppgifter	inga uppgifter
Lionel Carnot	Independent Director	8.4yrs	inga uppgifter	0.15% $ 2.8m
Quan Dong Nguyen	Member of Scientific Advisory Board	3.5yrs	inga uppgifter	inga uppgifter
Robert Warner	Independent Director	2yrs	inga uppgifter	0.017% $ 303.6k
Arshad Khanani	Chair of Retina Scientific Advisory Board & Independent Director	3.5yrs	inga uppgifter	0.014% $ 256.6k
Anat Loewenstein	Member of Scientific Advisory Board	3.5yrs	inga uppgifter	inga uppgifter
Pablo Villoslada	Member of Scientific Advisory Board	3.5yrs	inga uppgifter	inga uppgifter

3.5yrs

Genomsnittlig anställningstid

58yo

Genomsnittlig ålder

Erfaren styrelse: OCS s styrelse anses vara erfaren ( 3.5 års genomsnittlig mandatperiod).

Företagsanalys och finansiella data Status

Uppgifter	Senast uppdaterad (UTC-tid)
Analys av företag	2026/05/22 09:01
Aktiekurs vid dagens slut	2026/05/22 00:00
Intäkter	2026/03/31
Årlig intjäning	2025/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

Paket	Uppgifter	Tidsram	Exempel US-källa
Företagets finansiella ställning	10 år	Resultaträkning Kassaflödesanalys Balansräkning	SEC Form 10-K SEC Form 10-Q
Analytikernas konsensusuppskattningar	+3 år	Prognos för finansiella poster Analytikernas prismål	Rapporter från analytiker Blue Matrix
Marknadspriser	30 år	Aktiekurser Utdelningar, splittar och åtgärder	ICE Marknadsdata SEC Form S-1
Ägarskap	10 år	Största aktieägare Insiderhandel	SEC Formulär 4 SEC Formulär 13D
Förvaltning	10 år	Ledningsgrupp Styrelse och verkställande direktörer	SEC Form 10-K SEC Form DEF 14A
Viktiga utvecklingstendenser	10 år	Företagsmeddelanden	SEC Formulär 8-K

^* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Oculis Holding AG bevakas av 12 analytiker. 10 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

Analytiker	Institution
Colleen Kusy	Baird
Jason Matthew Gerberry	BofA Global Research
Daniil Gataulin	Chardan Capital Markets, LLC

Oculis Holding Förvaltning

Förvaltning kriterier kontrolleras 2/4

Viktig information

Senaste uppdateringar av ledningen

Oculis Holding Ag Announces Board and Committee Changes

Oculis Holding AG, Annual General Meeting, Mar 23, 2026

Oculis Holding AG Appoints Katie Kazem as Chief Legal Officer

Oculis Holding AG Announces Executive Appointments

Oculis Holding AG, Annual General Meeting, Jun 04, 2025

Oculis Holding AG Announces Appointment of Daniel S. Char as Chief Legal Officer

Recent updates

Oculis Shareholders Approve Expanded Share Capacity and New Director at 2026 Annual Meeting

Oculis Holding Ag Announces Board and Committee Changes

Oculis Holding AG Announces Agreement With FDA on Special Protocol Assessment for Optic Neuritis Registrational Trial

Oculis Holding AG Presents Latest Findings from DME AWARE Delphi Study and Provides Update on OCS-01 Eye Drop Therapy

Oculis Holding AG Announces Completion of Last Patient Visit in Phase 3 Diamond Program with OCS-01 Eye Drops for Treatment of Diabetic Macular Edema

Oculis Holding AG, Annual General Meeting, Mar 23, 2026

Oculis Holding Ag Presents Acuity Phase 2 Data with Privosegtor At North American Neuro-Ophthalmology Society Annual Meeting

Oculis Holding AG has filed a Follow-on Equity Offering in the amount of $100 million.

Oculis Holding AG Appoints Katie Kazem as Chief Legal Officer

Oculis Holding Ag Announces the Transformative Potential of Its Late-Stage Pipeline

Oculis Holding AG Announces U.S. FDA Breakthrough Therapy Designation Granted to Privosegtor for Treatment of Optic Neuritis

Oculis Holding AG to Report Q3, 2026 Results on Nov 05, 2026

Oculis Holding AG has filed a Follow-on Equity Offering in the amount of $109.999985 million.

Oculis Holding AG Announces Executive Appointments

Oculis Holding AG, Annual General Meeting, Jun 04, 2025

Oculis Holding AG Hosts R&D Event to Showcase Progress on All Three Pipeline Assets

Oculis Holding AG Completes Enrollment in Both Diamond Phase 3 Trials of OCS-01 in Diabetic Macular Edema

Oculis Is An Interesting Growth Bet On Non-Invasive Eye Care

Oculis Holding AG to Report Q4, 2024 Results on Mar 10, 2025

Oculis Announces Positive Topline Results with OCS-05 in the Phase 2 ACUITY Trial

Oculis: Lack Of Coverage Only Real Risk For This Solid Company

Oculis Holding AG Announces Appointment of Daniel S. Char as Chief Legal Officer

Oculis Holding AG Appoints Sharon Klier as Chief Development Officer

Oculis Holding AG to Report Q2, 2024 Results on Aug 14, 2024

Oculis Holding AG Announces Positive Topline Results of Phase 2b RelieF Trial with Licaminlimab Designed to Transform the Treatment Paradigm of Dry Eye Disease with a Precision Medicine Strategy

Oculis Holding AG Announces Board and Committee Appointments

First quarter 2024 earnings released: CHF0.44 loss per share (vs CHF1.27 loss in 1Q 2023)

Oculis Holding AG has filed a Follow-on Equity Offering in the amount of $100 million.

Oculis Holding AG, Annual General Meeting, May 29, 2024

Oculis Holding AG has completed a Follow-on Equity Offering in the amount of $58.75 million.

Oculis Holding AG has filed a Follow-on Equity Offering in the amount of $58.75 million.

Oculis Holding AG Strengthens its Executive Leadership Team with the Appointment of Snehal Shah as President of Research & Development

Oculis Holding Ag Announces Positive Results from Phase 3 Optimize-1 Trial of Once Daily Ocs-01 for the Treatment of Inflammation and Pain Following Cataract Surgery

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Revenue and earnings growth

Oculis Announces First Patient First Visit in Phase 3 OPTIMIZE-2 Trial of OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery

Oculis Holding AG Announces First Patient First Visit in Phase 3 DIAMOND-1 Trial of OCS-01 Eye Drop in Diabetic Macular Edema

Oculis Announces First Patient First Visit in Phase 2b RELIEF Trial of Topical Anti-TNF ALPHA> Licaminlimab (OCS-02) in Dry Eye Disease

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Oculis Holding AG announced that it has received $71.18891 million in funding from a group of investors

Oculis Holding AG Announces Positive Phase 3 Stage 1 Diamond Trial Results of OCS-01 in Diabetic Macular Edema Presented at 23rd EURETINA Congress

Oculis Holding to Present Late-Breaking Abstract at the 23rd EURETINA Congress on Positive Phase 3 Stage 1 Diamond Trial Results for Diabetic Macular Edema

New major risk - Revenue and earnings growth

Oculis Holding AG Appoints Rebecca Weil as Chief Commercial Officer

Second quarter 2023 earnings released: CHF0.38 loss per share (vs CHF3.29 loss in 2Q 2022)

Oculis Holding Ag Announces Positive Top Line Results from Its Phase 3 Optimize Trial with Ocs-01 Eye Drops

Oculis Holding AG to Host an R&D Retina Day to Showcase Clinical Programs Targeting Diabetic Macular Edema and Other Retina Diseases

High number of new and inexperienced directors